Enterprise Value

481.7M

Cash

68.78M

Avg Qtr Burn

-25.55M

Short % of Float

2.86%

Insider Ownership

10.05%

Institutional Own.

61.46%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Botaretigene sparoparvovec (AAV-RPGR) Details
Genetic disorder, Eye disease , X-linked retinitis pigmentosa

Phase 3

Data readout

AAV-RPE65 test Details
Eye disease , Retinal dystrophy

Phase 3

Initiation

AAV-CNGA3 Details
Achromatopsia

Phase 2b

Initiation

AAV-CNGB3 Details
Achromatopsia, Genetic disorder, Skin disease/disorder, Autosomal recessive congenital ichthyosis

Phase 1/2

Update

AAV-hAQP1 Details
Salivary gland

Phase 1

Data readout

AAV-GAD Details
Parkinson's disease

Phase 1

Update